Latest Conference Articles

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers

Carlton Brown Describes Key Messages of the ONS Congress

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Oral oncolytics are frequently used in cancer treatment and they make up approximately 25% of the medications in the oncology pipeline

Honorary Mistress of Ceremonies Cynthia Nixon kicked off the ONS 36th Annual Congress Cure magazine Extraordinary Healer Award with a rousing tribute

Lymphedema is the treatment-induced buildup of extra lymph fluid in tissues that causes discomforting and potentially debilitating swelling of the limbs

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Social media programs allow oncology nurses to network, share information, and learn evidence-based practices

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Elizabeth Blasiak on the Significance of the ONS Congress

Prostate cancer affects 1 of every 6 men in the United States

Traditional, linear regimen of prostate cancer treatment may need to be reexamined as oncologists learn new ways to incorporate new therapies

Initial clinical findings indicate that results with radiotherapies sometime improve when combined with immunotherapy

Immunotherapies again made headlines in oncology last month

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized high-risk prostate cancer patients

Screening for prostate cancer does work, despite controversy about its efficacy, according to IPCC Co-chair Leonard G. Gomella

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

As research into novel vaccine approaches for treating advanced prostate cancer continues...

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer